• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Recombinant Vaccines Market Size

    ID: MRFR/Pharma/4672-HCR
    100 Pages
    Rahul Gotadki
    October 2025

    Recombinant Vaccines Market Research Report Information: By Product (Subunit Recombinant and Attenuated Recombinant Vaccines), by Disease (Cancer, Pneumococcal Disease, Hepatitis B, and DPT), and End-Users (Pediatrics, Adults, and Veterinary) - Global Forecast Till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Recombinant Vaccines Market Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Recombinant Vaccines Size

    Recombinant Vaccines Market Growth Projections and Opportunities

    The global healthcare landscape has a game changer known as the Recombinant Vaccines Market that represents a transformative approach to vaccine development. The basic steps to create recombinant vaccines include gene insertion into host organisms and expression of proteins, which induce an immune reaction in the body. Consequently, this methodology has been instrumental in developing vaccines for various communicable diseases including Hepatitis B, Human Papilloma Virus (HPV) and Influenza.

    A particular advantage of these vaccines is their safety profile. The traditional vaccines are often based on attenuated or inactivated forms of pathogens that may pose minor risk of infection to some individuals. Conversely, non-infectious elements are used by recombinant vaccines thereby reducing possibility of side effects. As such, the issue of safety has positioned recombinant vaccinations as the preferred choice for immunization in vulnerable areas such as among babies and those with weakened immunity.

    Infectious diseases have been effectively prevented and controlled through the Recombinant Vaccines Market. For example, hepatitis B vaccine, which was among the first recombinant vaccines created has significantly contributed towards lowering the burden of this viral infection worldwide. Similarly, there exist recombinant HPV vaccines that have been helpful/ useful in preventing cervical cancer thereby pointing out how novel forms of immunization bring significant changes in public health.

    New emerging infectious threats also drive growth of recombinant vaccine development by market players due to technological advancements. This happened after COVID-19 pandemic struck leading to immediate research innovations that saw creation of recombinant vaccines against SARS-CoV-2 virus. Such interventions have demonstrated high efficacy in prevention severe illness and transmission hence indicating versatility inherent within recombination technology when it comes to managing emerging challenges in public health.

    The Recombinant Vaccines Market is present globally with great uptake whether it be developed or developing regions. Global organizations international agencies such like government departments and non-governmental organizations are promoting the use of recombinant vaccines by making sure every person in need gets them especially in order to eradicate disparities related to health. The need for cooperation while distributing these vaccines globally has been highlighted by initiatives aimed at low resource settings such as COVAX.

    This might impede accessibility in low-income areas due to high production and distribution costs experienced within the market. As a result, partnerships, technology transfer agreements and exploration of novel production techniques have been put in place to address these challenges with respect to affordability while increasing scalability.

    Growth and innovation lie ahead for the Recombinant Vaccines Market. Currently, research efforts are underway to expand the range of infectious diseases targeted by recombinant vaccines. Also important is that vaccine delivery technologies including mRNA platforms have seen tremendous breakthroughs that will eventually shape this field transforming it into one which can offer quick responses towards emerging threats.

    Recombinant Vaccines Market Size Graph

    Market Summary

    The Global Recombinant Vaccines Market is projected to experience substantial growth from 0.36 USD Billion in 2024 to 1.94 USD Billion by 2035.

    Key Market Trends & Highlights

    Global Recombinant Vaccines Key Trends and Highlights

    • The market is expected to grow at a compound annual growth rate of 16.56% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 1.94 USD Billion, indicating robust expansion.
    • In 2024, the market is valued at 0.36 USD Billion, highlighting its current size and potential for growth.
    • Growing adoption of recombinant vaccine technology due to increasing awareness of vaccine-preventable diseases is a major market driver.

    Market Size & Forecast

    2024 Market Size 0.36 (USD Billion)
    2035 Market Size 1.94 (USD Billion)
    CAGR (2025-2035) 16.56%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Abiomed, Emergent Bio Solutions, Inc., GlaxoSmithKline, Johnson & Johnson, Sanofi Pasteur SA, Serum Institute of India Pvt. Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo, Pfizer, Inc.

    Market Trends

    The ongoing advancements in biotechnology are likely to enhance the efficacy and accessibility of recombinant vaccines, thereby playing a crucial role in global health initiatives.

    World Health Organization (WHO)

    Recombinant Vaccines Market Market Drivers

    Government Initiatives and Funding

    Government initiatives and funding significantly influence the Global Recombinant Vaccines Market Industry. Many countries are increasing their investments in vaccine research and development to combat infectious diseases. For example, national health agencies are allocating substantial budgets to support the development of recombinant vaccines, which are often seen as a cost-effective solution for public health challenges. These initiatives not only facilitate the advancement of vaccine technology but also encourage collaboration between public and private sectors. As governments recognize the critical role of vaccines in safeguarding public health, the financial backing for recombinant vaccine projects is expected to grow, thereby enhancing the market landscape.

    Rising Demand for Preventive Healthcare

    The Global Recombinant Vaccines Market Industry experiences a notable surge in demand for preventive healthcare solutions. As populations become increasingly aware of the importance of vaccination in preventing infectious diseases, the market is projected to grow from 0.36 USD Billion in 2024 to an estimated 1.94 USD Billion by 2035. This growth indicates a compound annual growth rate (CAGR) of 16.56% from 2025 to 2035. Governments and health organizations are actively promoting vaccination programs, which further drives the demand for recombinant vaccines. This trend reflects a broader shift towards proactive health management, underscoring the significance of vaccines in public health strategies.

    Increasing Incidence of Infectious Diseases

    The rising incidence of infectious diseases is a crucial driver of the Global Recombinant Vaccines Market Industry. With the emergence of new pathogens and the resurgence of previously controlled diseases, the need for effective vaccination strategies has never been more pressing. This trend is particularly evident in regions experiencing outbreaks, where recombinant vaccines can provide rapid responses to emerging health threats. The World Health Organization and other health bodies emphasize the importance of vaccination in controlling disease spread. Consequently, the demand for recombinant vaccines is likely to increase, as they offer a viable solution to mitigate the impact of infectious diseases on global health.

    Technological Advancements in Vaccine Development

    Technological innovations play a pivotal role in shaping the Global Recombinant Vaccines Market Industry. Advances in genetic engineering and biotechnology have streamlined the development of recombinant vaccines, enhancing their efficacy and safety profiles. For instance, the use of recombinant DNA technology allows for the rapid production of vaccines tailored to specific pathogens. This capability not only accelerates the vaccine development process but also ensures a more robust immune response. As research institutions and pharmaceutical companies continue to invest in these technologies, the market is likely to witness an influx of novel vaccines, further propelling its growth and expanding the range of diseases that can be effectively targeted.

    Growing Public Awareness and Acceptance of Vaccines

    Public awareness and acceptance of vaccines are essential factors driving the Global Recombinant Vaccines Market Industry. Educational campaigns and outreach programs have significantly improved understanding of vaccine benefits, leading to higher vaccination rates. This trend is particularly evident in developing countries, where initiatives aimed at increasing vaccine literacy have resulted in greater public trust in vaccination programs. As communities become more informed about the role of vaccines in preventing diseases, the demand for recombinant vaccines is expected to rise. This growing acceptance not only supports public health objectives but also encourages investment in vaccine development, further stimulating market growth.

    Market Segment Insights

    Regional Insights

    Key Companies in the Recombinant Vaccines Market market include

    Industry Developments

    Future Outlook

    Recombinant Vaccines Market Future Outlook

    The Global Recombinant Vaccines Market is projected to grow at a 16.56% CAGR from 2024 to 2035, driven by technological advancements, increasing disease prevalence, and rising healthcare investments.

    New opportunities lie in:

    • Develop novel adjuvants to enhance vaccine efficacy and market differentiation.
    • Expand production capabilities in emerging markets to meet rising global demand.
    • Invest in digital health solutions for vaccine distribution and patient engagement.

    By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in global healthcare innovation.

    Market Segmentation

    Market Segmentation

    Recombinant Vaccines Market Segmentation   

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 0.29 (USD Billion)
    Market Size 2024 0.36 (USD Billion)
    Market Size 2032 1.62 (USD Billion)
    Compound Annual Growth Rate (CAGR) 6.24 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Abiomed, Emergent Bio Solutions, Inc., GlaxoSmithKline, Johnson & Johnson, Sanofi Pasteur SA, Serum Institute of India Pvt. Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo, Pfizer, Inc.
      Key Market Opportunities ·  Raising awareness of healthcare, favorable reimbursement policies ·  Increasing innovations in research and development of drugs, and vaccines ·  Rising average income of individuals
      Key Market Drivers ·  Increasing technical advanced devices ·  Increasing number of regulatory approvals ·  The high prevalence of infectious diseases ·  Growing penetration of key market players

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    What is the growth rate of the global recombinant vaccines market?

    The global recombinant vaccines market is expected to expand at 6.24% CAGR from 2024 to 2032.

    Who are the major players of the global recombinant vaccines market?

    Mitsubishi Tanabe Pharma Corporation, Johnson & Johnson, Pfizer, Inc., GlaxoSmithKline, Daiichi Sankyo, Serum Institute of India Pvt. Ltd, Emergent Bio Solutions, Inc., Sanofi Pasteur SA, and Abiomed are major players in the global recombinant vaccines market.

    What are the restraining factors of the global recombinant vaccines market?

    High costs of vaccines and huge risks associated with attenuated vaccines are factors which can hamper the global recombinant vaccines market.

    Which region can dominate in the global recombinant vaccines market?

    The global recombinant vaccines market is led by the Americas due to rapid strides in molecular biology in the region.

    What are major drivers of the global recombinant vaccines market?

    High prevalence of diseases and large number of approvals are major drivers of the global recombinant vaccines market.

    1.     Global Recombinant Vaccines Market by End-Users, 2020–2027,

    Recombinant Vaccines Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials